🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

72+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 12 of 72 recruiting trials for “primary-vitreoretinal-large-b-cell-lymphoma”

Phase 2, PHASE3RecruitingNCT05139017 ↗

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

👨‍⚕️ Medical Director, Merck Sharp & Dohme LLC📍 119 sites📅 Started Jan 2022View details ↗
Phase 2RecruitingNCT05552937 ↗

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

🏥 Beijing InnoCare Pharma Tech Co., Ltd.📍 1 site📅 Started Sep 2021View details ↗
Enrolling by InvitationNCT05690191 ↗

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

👨‍⚕️ Bingzong LI, Second Affiliated Hospital of Soochow University📍 1 site📅 Started Jun 2021View details ↗
Phase 1RecruitingNCT04609046 ↗

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

👨‍⚕️ Alvaro J Alencar, Alliance for Clinical Trials in Oncology📍 54 sites📅 Started May 2021View details ↗
Phase 3RecruitingNCT04442412 ↗

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

👨‍⚕️ Francesco Merli, Dott., Reggio Emilia - Azienda Unitа Sanitaria Locale-IRCCS📍 49 sites📅 Started Mar 2021View details ↗
Phase 1, PHASE2RecruitingNCT04836507 ↗

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

🏥 Curocell Inc.📍 1 site📅 Started Mar 2021View details ↗
Phase 1Enrolling by InvitationNCT04488354 ↗

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

🏥 Calibr, a division of Scripps Research📍 8 sites📅 Started Jan 2021View details ↗
Enrolling by InvitationNCT04491721 ↗

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

👨‍⚕️ Yuankai Shi, Doctor, Chinese Academy of Medical Sciences📍 1 site📅 Started Jul 2020View details ↗
Phase 1, PHASE2RecruitingNCT04432714 ↗

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

👨‍⚕️ Wei Xu, M.D., Ph.D, The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)📍 1 site📅 Started Jun 2020View details ↗
Phase 2RecruitingNCT03936153 ↗

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

👨‍⚕️ Yuankai SHI, Prof, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 23 sites📅 Started Jan 2020View details ↗
Phase 2RecruitingNCT03758989 ↗

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

👨‍⚕️ Carla Casulo, University of Rochester📍 1 site📅 Started May 2019View details ↗
NARecruitingNCT02964858 ↗

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

👨‍⚕️ Jayant Sastri Goda, M.D, Professor,Tata Memorial Centre📍 1 site📅 Started Nov 2016View details ↗
← PreviousPage 4 of 4

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →